Regarding the impact of low-dose IL-2 treatment on established AD biomarkers and clinical scales, 21 weeks of IL-2 q4wks administration sustainabily increased number of Tregs, improved CSF soluble Aβ42 levels (a possible indicator of decreased amyloid β pathology) and showed promising trends on clinical endpoints. Here, IL2 is linked to Alzheimer disease.